🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

AstraZeneca Pharma India Limited ASTRAZEN NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.astrazeneca.in
Company Profile ↓
₹6,101.00
-29.33% 1Y
Mkt Cap₹15,252.50 Cr
P/E89.92
P/B16.72
Div. Yield0.61%
52W High₹9,783.79
52W Low₹5,719.50
Book Value₹349.12
EPS (TTM)₹67.85

Company Overview

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes. The company serves distributors, hospitals, and government institutions. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 21.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 25.5%.

Consistent Profit Growth

Net profit has compounded at 23.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 31.3% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.13.

Recent Developments

  • Mar 2026 Revenue of ₹2,272.58 Cr (+32.6% YoY); net profit ₹187.52 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +29.7%, earnings -32.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 31.3%, profit CAGR 23.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:31.34%
1 Year:29.70%

Compounded Profit Growth

5 Years:23.61%
1 Year:-32.10%

Stock Price Performance

1 Year:-29.33%
6 Months:-27.61%
3 Months:-23.45%
1 Month:-9.10%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 9% of range
₹5,719.50 ₹9,783.79
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)41.92 · Neutral
Price Performance
1M-9.10%
3M-23.45%
6M-27.61%
1Y-29.33%
Valuation vs Sector

P/E of 89.92 is above the sector median of 35.90 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 21.5%.
  • Healthy ROCE of 25.5%.
  • Compounding revenue at 31.3% over 5 years.
  • Profit CAGR of 23.6% over 5 years.

CONS

  • Trading at a high P/E of 89.9.
  • Trading 37.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
89.92
Industry PE
35.90
Forward P/E est.
132.43
PEG Ratio
-
Book Value
₹349.12
Price to Book
16.72
P/S
6.00
EV/EBITDA
61.87
Dividend Yield
0.61%

Growth (CAGR)

Revenue 5Y
31.34%
Profit 5Y
23.61%
Revenue (YoY)
29.70%
Earnings (YoY)
-32.10%

Profitability & Returns

ROCE
25.48%
ROE
21.49%
ROA
9.43%
Profit Margin
6.97%
Op Margin
6.40%
Gross Margin
36.83%
EPS (Latest Qtr)
₹17.95
EPS (TTM)
₹67.85

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
0.73
Current Ratio
1.77
Debt
₹110.66 Cr
Total Assets
₹1,989.10 Cr
Current Assets
₹1,739.93 Cr
Working Capital
₹758.12 Cr

Ownership

Promoter Holding
81.48%
Chg in Prom Hold
-0.10%
FII / Inst Holding
8.97%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹15,252.50 Cr
Total Revenue (TTM)
₹2,432.06 Cr
EBITDA
₹225.65 Cr
Free Cash Flow
₹-18.75 Cr
Operating Cash Flow
₹-15.14 Cr
Shares Outstanding
₹2.50 Cr
Gross Margin
36.83%
Payout Ratio
47.17%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ASTRAZEN AstraZeneca Pharma India Limited NSEPHARMA 6,101.00 89.92 ₹15,252.50 Cr 0.61% 25.48% 21.49% 31.34% 23.61%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -480.48 Cr526.31 Cr559.09 Cr611.57 Cr578.61 Cr
Cost of Revenue -259.61 Cr295.41 Cr324.49 Cr366.39 Cr394.25 Cr
Gross Profit -220.87 Cr230.90 Cr234.60 Cr245.18 Cr184.36 Cr
Operating Expenses -152.19 Cr166.36 Cr161.99 Cr204.19 Cr129.05 Cr
Operating Income -68.68 Cr64.54 Cr72.61 Cr40.99 Cr55.31 Cr
EBITDA -96.84 Cr91.99 Cr76.06 Cr51.44 Cr65.78 Cr
Interest Expense -68.00 L72.00 L67.00 L1.06 Cr2.04 Cr
Pretax Income -78.47 Cr74.70 Cr72.82 Cr46.54 Cr58.14 Cr
Tax Provision -20.22 Cr18.87 Cr18.60 Cr13.95 Cr13.26 Cr
Net Income -58.25 Cr55.83 Cr54.22 Cr32.59 Cr44.88 Cr
Diluted EPS -23.3022.3321.6913.0417.95

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1,002.97 Cr1,295.53 Cr1,713.29 Cr2,272.58 Cr
Cost of Revenue -425.26 Cr673.26 Cr1,000.58 Cr1,488.69 Cr
Gross Profit -577.71 Cr622.27 Cr712.71 Cr783.89 Cr
Operating Expenses -428.82 Cr450.84 Cr497.90 Cr549.25 Cr
Operating Income -148.89 Cr171.43 Cr214.81 Cr234.64 Cr
EBITDA -150.99 Cr235.68 Cr197.81 Cr285.27 Cr
Interest Expense -63.00 L1.20 Cr1.46 Cr4.49 Cr
Pretax Income -134.10 Cr219.54 Cr156.36 Cr252.20 Cr
Tax Provision -34.81 Cr58.03 Cr40.62 Cr64.68 Cr
Net Income -99.29 Cr161.51 Cr115.74 Cr187.52 Cr
Diluted EPS -39.7064.6046.3075.00

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -984.87 Cr1,078.03 Cr1,518.12 Cr1,989.10 Cr
Current Assets -835.47 Cr932.71 Cr1,342.35 Cr1,739.93 Cr
Cash & Equivalents -500.34 Cr505.57 Cr536.14 Cr447.72 Cr
Inventory -190.21 Cr227.88 Cr548.50 Cr1,027.33 Cr
Receivables -107.52 Cr153.13 Cr184.88 Cr213.68 Cr
Total Liabilities -396.18 Cr366.11 Cr747.77 Cr1,116.31 Cr
Current Liabilities -383.93 Cr357.12 Cr703.00 Cr981.81 Cr
Long Term Debt -----
Total Debt -7.21 Cr4.59 Cr35.73 Cr110.66 Cr
Total Equity -588.69 Cr711.92 Cr770.35 Cr872.79 Cr
Shares Outstanding -2.50 Cr2.50 Cr2.50 Cr2.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -58.29 Cr27.87 Cr65.36 Cr-15.14 Cr
Investing Cash Flow -18.11 Cr21.74 Cr30.80 Cr18.69 Cr
Financing Cash Flow --24.48 Cr-44.38 Cr-65.59 Cr-91.97 Cr
Capital Expenditure --8.52 Cr-10.76 Cr-1.75 Cr-3.61 Cr
Free Cash Flow -49.77 Cr17.11 Cr63.61 Cr-18.75 Cr
Net Change in Cash -51.92 Cr5.23 Cr30.57 Cr-88.42 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -57.6%48.0%41.6%34.5%
Operating Margin % -14.8%13.2%12.5%10.3%
Net Margin % -9.9%12.5%6.8%8.3%
ROE % -16.9%22.7%15.0%21.5%
ROCE % -24.8%23.8%26.4%23.3%

Shareholding Pattern

Insiders
81.48%
Institutions
8.97%
Public Float
48.41%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ASTRAZEN

Google News Wed, 21 Oct 2026

Is AstraZeneca (AZN) Stock Cheap? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQM2psaWRJWDBLUEt2THRTb2lVcEgyRk1aeXJTalkxSi1uVzZiSkVKQUx0aEpDYW04aWx1alJMUlo1S0dWV3JZX2k3d3RvOExoMXEzLTJoNmd2ZURpWTAtWFFXN1lDZFZJLUNJR01ZS3J2WEdwRGdOOU1kd0MwUnpVaGFxMU5RTHBSeERXUz…

Google News hu, 22 Oct 2026

Why Is AstraZeneca Stock Trading Higher Today? - AstraZeneca (NYSE:AZN) - Benzinga

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbk1pT0RjZlF2SHVxZWVXVE01cVlrQjJzR0VyQTM2cTBsZkN3STJId0c4WEpXaTVLUHZfT09MNXpiMF8tWGFSb2p4d1V1RW5YamtUdmlCVGhyMWhUSEZXMWJHS2Fzci1TaTJrU0xicnIzQm9zY3J4VU10MV84Qi1IdjJYLVhkLV8wMmxZQ1…

Google News ue, 29 Sep 2026

How Summit Therapeutics Stock Could Surge 162% After AstraZeneca Investment - Barron's

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQS3hQa2lOX2trLWgtT1A2VFBCZGZzNk16cFdPdnA1MkNtR2hXTEJIeUhBMXB2YXhOUk9KLU9LdkJPV3Mxa2VoYl9iejJyUkZwbUhncmZoaDJzb3p2SmxodVJjLXpERi1IaW93cFJSMjhsQ3lFOFpJc0ptUFVQVVMzYTF1YlVEMDZNSFFGbD…

Google News ue, 29 Sep 2026

A $2 Billion Reason Why AstraZeneca Stock Is Down Today - Barchart.com

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNcWpkUWF2alFtU1FudjIwNWtXVVBoOGlYNDBhU0xZcS1EeVE0em9mWUJSeEEwX3I2OTdzR3FQbEJZOHk3V1JXaVIyUnlRUU9xeXVLdmtnWjcwaVBIY2puNUQ2ZHhSaXpiNjFFektmQzdublBxZDlUUjVoN29xZWt5eFNCOVZJZkZXOHNiLX…

Google News hu, 06 Aug 2026

Deal or No Deal, AstraZeneca Stock Is a Bargain - WSJ

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQVjYyYlNzdWlTM3E3dU96dVZ6cVdxaXhoalZpMHBDaWxSUEx4d2llQUtBODAxUzgwX0p4S3ZqOWZjZDRvdVdaUWhFcERPVnN2Rzg2RzFJeWk0cWNEcXlmTWlCTkNwZTB3bFluSzlrM0I0MkNZdExwVWxZS3h6cnJSOXdEZDBrMm9USHZR?o…

Google News ue, 29 Sep 2026

Why is AstraZeneca stock rallying today? - Investing.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPOUJSUVdnLXNQb3RLLUIzTHo1VnlVT19GVk15bHF1VV96RmFtWGJJRjJLUFZpb2JLSTV2UlBzT1lyNWk3N1FvZ3JvcVM4QThma2Nzc1l4UWN3T3lrQnQwT1hEZmhNYV9nd0ZjYWJfX3g5NFktVzFzbl84VVNLQXc4YkF5UEpaeWttaUkyQ0…

ASTRAZEN — Frequently Asked Questions

What is the current share price of AstraZeneca Pharma India Limited (ASTRAZEN)?

As of 2026-10-24 04:55 IST, AstraZeneca Pharma India Limited (ASTRAZEN) trades at ₹6,101.00 on NSE. Its 52-week range is ₹5,719.50 to ₹9,783.79.

What is the market capitalisation of ASTRAZEN?

AstraZeneca Pharma India Limited (ASTRAZEN) has a market capitalisation of ₹15,252.50 Cr on NSE.

What is the P/E ratio of ASTRAZEN?

ASTRAZEN trades at a trailing price-to-earnings (P/E) ratio of 89.92. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 16.72.

Does ASTRAZEN pay a dividend?

AstraZeneca Pharma India Limited (ASTRAZEN) currently offers a dividend yield of 0.61%.

What is the return on equity (ROE) of ASTRAZEN?

ASTRAZEN has a return on equity (ROE) of 21.49%. Its return on capital employed (ROCE) is 25.48%.

Is ASTRAZEN a good stock to buy?

This page provides a data-driven analysis of AstraZeneca Pharma India Limited (ASTRAZEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space